Login
Israel-Hamas Conflict
Military
World Cup
Protestors
Donald Trump
Social Media
Wrestling
Cryptocurrency
Artificial Intelligence
Soccer
Bitcoin
Immigration
Stock Markets
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

CRISPR discusses CASGEVY growth and future of allogeneic CAR-T therapies

Summary by BioProcess International
CRISPR Therapeutics CEO outlines plans to expand allogeneic CAR-T therapies for autoimmune diseases while scaling CASGEVY's global reach across eight jurisdictions with a $2.2M price point
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
BioProcess InternationalBioProcess International

CRISPR discusses CASGEVY growth and future of allogeneic CAR-T therapies

CRISPR Therapeutics CEO outlines plans to expand allogeneic CAR-T therapies for autoimmune diseases while scaling CASGEVY's global reach across eight jurisdictions with a $2.2M price point

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

BioProcess International broke the news in on Tuesday, June 10, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

CRISPR

CRISPR

News
For You
SearchBlindspotLocal